Biopoly has filed a notice of an exempt offering of securities to raise $7,000,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Biopoly is raising $7,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Ryan Schlotterback played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Biopoly
BioPoly was established to provide a treatment option for painful cartilage lesions between the extremes of biological solutions and total joint replacement. Utilizing a patented material that is self-lubricating for improved wear properties (via a biological enhancement with Hyaluronic Acid) the BioPoly RS devices are uniquely designed to replace only the damaged cartilage. Therefore, patients can quickly recover and return to pain-free, active lifestyles. BioPoly RS devices are currently available for femoral condyle, trochlear facets, trochlear groove, patella, and humeral head applications. Patients out to >10 years have experienced a significant reduction in pain and have shown improved quality of life. Additional orthopedic applications are currently in development. BioPoly serves healthcare professionals and their patients throughout the world from our headquarters in Fort Wayne, Indiana, USA.
To learn more about Biopoly, visit http://www.biopolyortho.com/
Contact:
Ryan Schlotterback, Chief Executive Officer
260-999-6163
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.